Ask a Question
    • NUBEQA®
    • Efficacy
    • Safety
    • Dosing
    • Reimbursement
    • Resources

    NUBEQA® Publications

    ARAMIS Preview

    ARAMIS Trial

     

    Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

    Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235-1246.

     

    Access
    arrow_outward
    ARASENS Preview

    ARASENS Trial

     

    Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

    Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132-1142.

     

    Access
    arrow_outward
    ARANOTE Preview

    ARANOTE Trial

     

    Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

    Saad F, Vjaters E, Shore N, Olmos D, Xing N, de Santana Gomes AJP, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42(36):4271-4281. doi:10.1200/JCO-24-01798.

    Access
    arrow_outward
    Access the NUBEQA® Homepage
    arrow_forward

    PP-NUB-CA-0687-1